Advertisement

---

GENOMEDX BIOSCIENCES

Validation Study of Decipher™ Genomic Prostate Cancer Test to be Published in Journal of Urology: Decipher Correctly Reclassifies 60 Percent of "High Risk" Patients as "Low Risk" and Identifies Patients Four Times More Likely to Develop Metastatic Prostate Cancer

[2013-06-25] - Decipher genomic test independently forecasts risk of metastatic disease better than PSA, Gleason Score, and other commonly used risk assessment tools as determined by clinical outcomes


New Study Demonstrates that GenomeDx's Decipher™ Test was Superior to Current Risk Assessment Tools in Predicting Metastatic Prostate Cancer

[2013-05-08] - Data Presented by at 2013 American Urological Association Annual Meeting


Study Shows GenomeDx's Decipher™ Test Effectively Predicts Rapid Metastatic Prostate Cancer

[2013-05-08] - Two Johns Hopkins University School of Medicine studies presented at the 2013 AUA Annual Meeting demonstrate Decipher's ability to outperform existing tools for predicting metastasis and disease progression


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers